Stem cell regenerative potential combined with nanotechnology and tissue engineering for myocardial regeneration

Current Stem Cell Research and Therapy

Volumn 8, Issue 4, 2013, Pages 292-303

  Calin, Manuela ^a,b   Stan, Daniela ^b   Simion, Viorel ^b  

^a PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

^b INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Cell transplantation; Myocardial infarction; Myocardial regeneration; Nanoparticles; Nanotechnology; Stem cells

Indexed keywords

8 QUINOLINOL INDIUM IN 111; ADENOVIRUS VECTOR; ANGIOPOIETIN 1; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; INTERLEUKIN 10; IRIDIUM; NANOPARTICLE; PADGEM PROTEIN; POLYAMIDOAMINE; QUANTUM DOT; RETROVIRUS VECTOR; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TISSUE SCAFFOLD; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN; VASCULOTROPIN 165;

ANGIOGENESIS; ARTICLE; BIOLUMINESCENCE; CELL DIFFERENTIATION; CELL HOMING; CELL LABELING; CELL MIGRATION; CELL REGENERATION; CELL SURVIVAL; CELL TRACKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA MODIFICATION; ENGRAFTMENT; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYBRID; HYDROGEL; MESENCHYMAL STEM CELL TRANSPLANTATION; NANOBIOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOACTIVITY; REPORTER GENE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL RESEARCH; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SURVIVAL; CELL TRACKING; GENE TRANSFER TECHNIQUES; HEART; HUMANS; MYOCARDIAL INFARCTION; NANOMEDICINE; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING;

EID: 84888092979     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X11308040005     Document Type: Article

References (163)

1. Mathur A, Martin JF. Stem cells and repair of the heart. Lancet 2004; 364(9429): 183-92.
2. Kehat I, Khimovich L, Caspi O, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004; 22(10): 1282-9.
3. Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361(9351): 45-6.
4. Haider H, Tan AC, Aziz S, Chachques JC, Sim EK. Myoblast transplantation for cardiac repair: a clinical perspective. Mol Ther 2004; 9(1): 14-23.
5. Planat-Benard V, Menard C, Andre M, et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 2004; 94(2): 223-9.
6. Liu J, Hu Q, Wang Z, et al. Autologous stem cell transplantation for myocardial repair. Am J Physiol Heart Circ Physiol 2004; 287(2): H501-11.
7. Wang L, Deng J, Tian W, et al. Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts. Am J Physiol Heart Circ Physiol 2009; 297(3): H1020-31.
8. Chiu RC. Adult stem cell therapy for heart failure. Expert Opin Biol Ther 2003; 3(2): 215-25.
9. Wei H, Ooi TH, Tan G, et al. Cell delivery and tracking in postmyocardial infarction cardiac stem cell therapy: an introduction for clinical researchers. Heart Fail Rev 2010; 15(1): 1-14.
10. Kang S, Yang YJ, Li CJ, Gao RL. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis 2008; 19(5): 327-35.
11. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med 2010; 5(1): 121-43.
12. Kim DE, Schellingerhout D, Ishii K, Shah K, Weissleder R. Imaging of stem cell recruitment to ischemic infarcts in a murine model. Stroke 2004; 35(4): 952-7.
13. Serganova I, Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl Med Biol 2005; 32(7): 763-80.
14. Srinivas M, Aarntzen EH, Bulte JW, et al. Imaging of cellular therapies. Adv Drug Deliv Rev 2010; 62(11): 1080-93.
15. La Francesca S. Nanotechnology and stem cell therapy for cardiovascular diseases: potential applications. Methodist Debakey Cardiovasc J 2012; 8(1): 28-35.
16. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005; 85(4): 1373-416.
17. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27(9): 1114-22.
18. Solanki A, Kim JD, Lee KB. Nanotechnology for regenerative medicine: nanomaterials for stem cell imaging. Nanomedicine (Lond) 2008; 3(4): 567-78.
19. Kustermann E, Roell W, Breitbach M, et al. Stem cell implantation in ischemic mouse heart: a high-resolution magnetic resonance imaging investigation. NMR Biomed 2005; 18(6): 362-70.
20. [] Kim YJ, Huh YM, Choe KO, et al. In vivo magnetic resonance imaging of injected mesenchymal stem cells in rat myocardial infarction; simultaneous cell tracking and left ventricular function measurement. Int J Cardiovasc Imaging 2009; 25 Suppl 1: 99-109.
21. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111(17): 2198-202.
22. Villa C, Erratico S, Razini P, et al. Stem cell tracking by nanotechnologies. Int J Mol Sci 2010; 11(3):1070-81.
23. Villa C, Erratico S, Razini P, et al. In vivo tracking of stem cell by nanotechnologies: future prospects for mouse to human translation. Tissue Eng Part B Rev 2011; 17(1): 1-11.
24. Ricles LM, Nam SY, Sokolov K, Emelianov SY, Suggs LJ. Function of mesenchymal stem cells following loading of gold nanotracers. Int J Nanomedicine 2011; 6: 407-16.
25. Cromer Berman SM, Walczak P, Bulte JW. Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 3(4): 343-55.
26. Bhirde A, Xie J, Swierczewska M, Chen X. Nanoparticles for cell labeling. Nanoscale 2011; 3(1): 142-53.
27. El-Sadik AO, El-Ansary A, Sabry SM. Nanoparticle-labeled stem cells: a novel therapeutic vehicle. Clin Pharmacol 2010; 2: 9-16.
28. Ferreira L. Nanoparticles as tools to study and control stem cells. J Cell Biochem 2009; 108(4): 746-52.
29. Matuszewski L, Persigehl T, Wall A, et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology 2005; 235(1): 155-61.
30. Kim D, Hong KS, Song J. The present status of cell tracking methods in animal models using magnetic resonance imaging technology. Mol Cells 2007; 23(2): 132-7.
31. Seymour L, Schacht E, Duncan R. The effect of size of polystyrene particles on their retention within the rat peritoneal compartment, and on their interaction with rat peritoneal macrophages In vitro. Cell Biol Int Rep 1991; 15(4): 277-86.
32. Basly B, Felder-Flesch D, Perriat P, et al. Dendronized iron oxide nanoparticles as contrast agents for MRI. Chem Commun (Camb) 2010; 46(6): 985-7.
33. [] Vittorio O, Duce SL, Pietrabissa A, Cuschieri A. Multiwall carbon nanotubes as MRI contrast agents for tracking stem cells. Nanotechnology 2011; 22(9): 095706.
34. [] Gul H, Lu W, Xu P, Xing J, Chen J. Magnetic carbon nanotube labelling for haematopoietic stem/progenitor cell tracking. Nanotechnology 2010; 21(15): 155101.
35. Himmelreich U, Hoehn M. Stem cell labeling for magnetic resonance imaging. Minim Invasive Ther Allied Technol 2008; 17(2): 132-42.
36. Garot J, Unterseeh T, Teiger E, et al. Magnetic resonance imaging of targeted catheter-based implantation of myogenic precursor cells into infarcted left ventricular myocardium. J Am Coll Cardiol 2003; 41(10): 1841-6.
37. Bara C, Ghodsizad A, Niehaus M, et al. In vivo echocardiographic imaging of transplanted human adult stem cells in the myocardium labeled with clinically applicable CliniMACS nanoparticles. J Am Soc Echocardiogr 2006; 19(5): 563-8.
38. Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, Marban E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010; 106(10):1570-81.
39. Kraitchman DL, Heldman AW, Atalar E, et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 2003; 107(18): 2290-3.
40. Kraitchman DL, Tatsumi M, Gilson WD, et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005; 112(10): 1451-61.
41. Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation 2003; 108(8): 1009-14.
42. Suzuki Y, Zhang S, Kundu P, Yeung AC, Robbins RC, Yang PC. In vitro comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides. Magn Reson Med 2007; 57(6): 1173-9.
43. Frank JA, Zywicke H, Jordan EK, et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 2002; 9 Suppl 2: S484-7.
44. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and In vivo tracking of stem cells. Nat Biotechnol 2001; 19(12): 1141-7.
45. van den Bos EJ, Wagner A, Mahrholdt H, et al. Improved efficacy of stem cell labeling for magnetic resonance imaging studies by the use of cationic liposomes. Cell Transplant 2003; 12(7): 743-56.
46. Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003; 228(2): 480-7.
47. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow In vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18(4): 410-4.
48. Kraitchman DL, Kedziorek DA, Bulte JW. MR imaging of transplanted stem cells in myocardial infarction. Methods Mol Biol 2011; 680: 141-52.
49. Schafer R, Kehlbach R, Muller M, et al. Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability. Cytotherapy 2009; 11(1): 68-78.
50. Kostura L, Kraitchman DL, Mackay AM, Pittenger MF, Bulte JW. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed 2004; 17(7): 513-7.
51. Bulte JW, Kraitchman DL, Mackay AM, Pittenger MF. Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood 2004; 104(10): 3410-2.
52. Au KW, Liao SY, Lee YK, et al. Effects of iron oxide nanoparticles on cardiac differentiation of embryonic stem cells. Biochem Biophys Res Commun 2009; 379(4): 898-903.
53. Chaudeurge A, Wilhelm C, Chen-Tournoux A, et al. Can Magnetic Targeting of Magnetically Labeled Circulating Cells Optimize Intramyocardial Cell Retention? Cell Transplant 2012; 21(4): 679-91
54. Song C, Xiang J, Tang J, et al. Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy. Hum Gene Ther 2011; 22(4): 439-49.
55. Yanai A, Hafeli UO, Metcalfe AL, et al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant 2012; 21(6): 1137-48.
56. Klabusay M, Scheer P, Doubek M, Rehakova K, Coupek P, Horky D. Retention of nanoparticles-labeled bone marrow mononuclear cells in the isolated ex vivo perfused heart after myocardial infarction in animal model. Exp Biol Med (Maywood) 2009; 234(2): 222-31.
57. Zhou R, Idiyatullin D, Moeller S, et al. SWIFT detection of SPIOlabeled stem cells grafted in the myocardium. Magn Reson Med 2010; 63(5): 1154-61.
58. Hung TC, Suzuki Y, Urashima T, et al. Multimodality evaluation of the viability of stem cells delivered into different zones of myocardial infarction. Circ Cardiovasc Imaging 2008; 1(1): 6-13.
59. Arai T, Kofidis T, Bulte JW, et al. Dual In vivo magnetic resonance evaluation of magnetically labeled mouse embryonic stem cells and cardiac function at 1.5 t. Magn Reson Med 2006; 55(1): 203-9.
60. Mani V, Adler E, Briley-Saebo KC, et al. Serial In vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model of myocardial infarction. Magn Reson Med 2008; 60(1): 73-81.
61. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005; 102(32): 11474-9.
62. Ruhparwar A, Ghodsizad A, Niehaus M, et al. Clinically applicable 7-Tesla magnetic resonance visualization of transplanted human adult stem cells labeled with CliniMACS nanoparticles. Thorac Cardiovasc Surg 2006; 54(7): 447-51.
63. Baklanov DV, Demuinck ED, Thompson CA, Pearlman JD. Novel double contrast MRI technique for intramyocardial detection of percutaneously transplanted autologous cells. Magn Reson Med. 2004; 52(6): 1438-42.
64. Terrovitis J, Stuber M, Youssef A, et al. Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation 2008; 117(12): 1555-62.
65. Amsalem Y, Mardor Y, Feinberg MS, et al. Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation 2007; 116(11 Suppl): I38-45.
66. Sadek HA, Garry DJ. Letter by Sadek and Garry regarding article, Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation 2008; 17(14): e306.
67. Grinnemo KH, Mansson A, Dellgren G, et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 2004; 127(5): 1293-300.
68. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108(6): 2114-20.
69. Chung J, Kee K, Barral JK, et al. In vivo molecular MRI of cell survival and teratoma formation following embryonic stem cell transplantation into the injured murine myocardium. Magn Reson Med 2011; 66(5): 1374-81.
70. Chakraborty SK, Fitzpatrick JA, Phillippi JA, et al. Cholera toxin B conjugated quantum dots for live cell labeling. Nano Lett 2007; 7(9): 2618-26.
71. Shah BS, Clark PA, Moioli EK, Stroscio MA, Mao JJ. Labeling of mesenchymal stem cells by bioconjugated quantum dots. Nano Lett 2007; 7(10): 3071-9.
72. Lin S, Xie X, Patel MR, et al. Quantum dot imaging for embryonic stem cells. BMC Biotechnol 2007; 7: 67.
73. Rosen AB, Kelly DJ, Schuldt AJ, et al. Finding fluorescent needles in the cardiac haystack: tracking human mesenchymal stem cells labeled with quantum dots for quantitative In vivo threedimensional fluorescence analysis. Stem Cells 2007; 25(8): 2128-38.
74. [] Nagarajan S, Zhang Y. Upconversion fluorescent nanoparticles as a potential tool for in-depth imaging. Nanotechnology 2011; 22(39): 395101.
75. Callera F, de Melo CM. Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells' migration into the injured site. Stem Cells Dev 2007; 16(3): 461-6.
76. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67(10): 1187-94.
77. Dai W, Hale SL, Kay GL, Jyrala AJ, Kloner RA. Delivering stem cells to the heart in a collagen matrix reduces relocation of cells to other organs as assessed by nanoparticle technology. Regen Med 2009; 4(3): 387-95.
78. Shah K, Hingtgen S, Kasmieh R, et al. Bimodal viral vectors and In vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 2008; 28(17): 4406-13.
79. Li Z, Suzuki Y, Huang M, et al. Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells 2008; 26(4): 864-73.
80. Kammili RK, Taylor DG, Xia J, et al. Generation of novel reporter stem cells and their application for molecular imaging of cardiacdifferentiated stem cells In vivo. Stem Cells Dev 2010; 19(9): 1437-48.
81. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for In vivo magnetic resonance imaging. Nat Med 2005; 11(4): 450-4.
82. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol 2007; 25(2): 217-9.
83. Gilad AA, Winnard PT, van Zijl PC, Bulte JW. Developing MR reporter genes: promises and pitfalls. NMR Biomed 2007; 20(3): 275-90.
84. Zurkiya O, Chan AW, Hu X. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Magn Reson Med 2008; 59(6): 1225-31.
85. Goldhawk DE, Lemaire C, McCreary CR, et al. Magnetic resonance imaging of cells overexpressing MagA, an endogenous contrast agent for live cell imaging. Mol Imaging 2009; 8(3): 129-39.
86. Kumar S, Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J 2007; 21(14): 3917-27.
87. Brenner S, Whiting-Theobald N, Kawai T, et al. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells 2004; 22(7): 1128-33.
88. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16(3): 571-9.
89. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14(2): 181-7.
90. Lum LG, Fok H, Sievers R, Abedi M, Quesenberry PJ, Lee RJ. Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium. Blood Cells Mol Dis 2004; 32(1): 82-7.
91. Lee RJ, Fang Q, Davol PA, et al. Antibody targeting of stem cells to infarcted myocardium. Stem Cells 2007; 25(3): 712-7.
92. Ko IK, Kean TJ, Dennis JE. Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials 2009; 30(22): 3702-10.
93. Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, Karp JM. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials 2010; 31(19): 5266-74.
94. Kim MH, Kino-oka M, Maruyama N, Saito A, Sawa Y, Taya M. Cardiomyogenic induction of human mesenchymal stem cells by altered Rho family GTPase expression on dendrimer-immobilized surface with D-glucose display. Biomaterials 2010; 31(30): 7666-77.
95. Penn MS, Mangi AA. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ Res 2008; 102(12): 1471-82.
96. Das H, George JC, Joseph M, et al. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One 2009; 4(10): e7325.
97. [] Kim SH, Moon HH, Kim HA, Hwang KC, Lee M, Choi D. Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther, 2011; 19(4): 741-50.
98. Chen SL, Zhu CC, Liu YQ, et al. Mesenchymal stem cells genetically modified with the angiopoietin-1 gene enhanced arteriogenesis in a porcine model of chronic myocardial ischaemia. J Int Med Res 2009; 37(1): 68-78.
99. Ye L, Haider H, Jiang S, et al. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 2007; 9(1): 15-22.
100. Zhu K, Guo C, Lai H, et al. Novel hyperbranched polyamidoamine nanoparticles for transfecting skeletal myoblasts with vascular endothelial growth factor gene for cardiac repair. J Mater Sci Mater Med 2011; 22(11): 2477-85.
101. Zhu K, Lai H, Guo C, Xu D, Wang C. Novel vascular endothelial growth factor gene delivery system-manipulated mesenchymal stem cells repair infarcted myocardium. Exp Biol Med (Maywood) 2012; 237(6): 678-87.
102. Ye L, Haider H, Tan R, et al. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 2007; 116(11 Suppl): I113-20.
103. Ye L, Zhang W, Su LP, et al. Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials 2011; 32(9): 2424-31.
104. Paul A, Binsalamah ZM, Khan AA, et al. A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials 2011; 32(32): 8304-18.
105. Paul A, Nayan M, Khan AA, Shum-Tim D, Prakash S. Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction. Int J Nanomedicine 2012; 7: 663-82.
106. Holladay C, Power K, Sefton M, O'Brien T, Gallagher WM, Pandit A. Functionalized scaffold-mediated interleukin 10 gene delivery significantly improves survival rates of stem cells In vivo. Mol Ther 2011; 19(5): 969-78.
107. Holladay CA, Duffy AM, Chen X, Sefton MV, O'Brien TD, Pandit AS. Recovery of cardiac function mediated by MSC and interleukin-10 plasmid functionalised scaffold. Biomaterials 2012; 33(5): 1303-14.
108. Wang H, Zhou J, Liu Z, Wang C. Injectable cardiac tissue engineering for the treatment of myocardial infarction. J Cell Mol Med 2010; 14(5): 1044-55.
109. Chiu LL, Iyer RK, Reis LA, Nunes SS, Radisic M. Cardiac tissue engineering: current state and perspectives. Front Biosci 2012; 17: 1533-50.
110. Ruvinov E, Harel-Adar T, Cohen S. Bioengineering the infarcted heart by applying bio-inspired materials. J Cardiovasc Transl Res 2011; 4(5): 559-74.
111. Karam JP, Muscari C, Montero-Menei CN. Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium. Biomaterials 2012; 33(23): 5683-95.
112. Ieda M, Tsuchihashi T, Ivey KN, et al. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 2009; 16(2): 233-44.
113. Rubart M, Pasumarthi KB, Nakajima H, Soonpaa MH, Nakajima HO, Field LJ. Physiological coupling of donor and host cardiomyocytes after cellular transplantation. Circ Res 2003; 92(11): 1217-24.
114. Soonpaa MH, Koh GY, Klug MG, Field LJ. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 1994; 264(5155): 98-101.
115. Li RK, Weisel RD, Mickle DA, et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg 2000; 119(1): 62-8.
116. Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci USA 2003; 100(13): 7808-11.
117. van Amerongen MJ, Bou-Gharios G, Popa E, et al. Bone marrowderived myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol 2008; 214(3): 377-86.
118. Lakshmanan R, Krishnan UM, Sethuraman S. Living cardiac patch: the elixir for cardiac regeneration. Expert Opin Biol Ther 2012; 12(12): 1623-40.
119. Alperin C, Zandstra PW, Woodhouse KA. Polyurethane films seeded with embryonic stem cell-derived cardiomyocytes for use in cardiac tissue engineering applications. Biomaterials 2005; 26(35): 7377-86.
120. Yang MC, Wang SS, Chou NK, et al. The cardiomyogenic differentiation of rat mesenchymal stem cells on silk fibroinpolysaccharide cardiac patches In vitro. Biomaterials 2009; 30(22): 3757-65.
121. Yang MC, Chi NH, Chou NK, et al. The influence of rat mesenchymal stem cell CD44 surface markers on cell growth, fibronectin expression, and cardiomyogenic differentiation on silk fibroin-Hyaluronic acid cardiac patches. Biomaterials 2010; 31(5): 854-62.
122. Lisi A, Briganti E, Ledda M, et al. A combined synthetic-fibrin scaffold supports growth and cardiomyogenic commitment of human placental derived stem cells. PLoS One 2012; 7(4): e34284.
123. Serrao GW, Turnbull IC, Ancukiewicz D, et al. Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells. Tissue Eng Part A 2012; 18(13-14): 1322-33.
124. Xing Y, Lv A, Wang L, Yan X, Zhao W, Cao F. Engineered myocardial tissues constructed In vivo using cardiomyocyte-like cells derived from bone marrow mesenchymal stem cells in rats. J Biomed Sci 2012; 19: 6.
125. Liau B, Christoforou N, Leong KW, Bursac N. Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. Biomaterials 2011; 32(35): 9180-7.
126. von Wattenwyl R, Blumenthal B, Heilmann C, et al. Scaffoldbased transplantation of vascular endothelial growth factoroverexpressing stem cells leads to neovascularization in ischemic myocardium but did not show a functional regenerative effect. ASAIO J 2012; 58(3): 268-74.
127. Fiumana E, Pasquinelli G, Foroni L, et al. Localization of mesenchymal stem cells grafted with a hyaluronan-based scaffold in the infarcted heart. J Surg Res 2013; 179(1): e21-9.
128. He W, Ye L, Li S, et al. Construction of vascularized cardiac tissue from genetically modified mouse embryonic stem cells. J Heart Lung Transplant 2012; 31(2): 204-12.
129. Kim DH, Kshitiz, Smith RR, et al. Nanopatterned cardiac cell patches promote stem cell niche formation and myocardial regeneration. Integr Biol (Camb) 2012; 4(9): 1019-33.
130. Paul A, Chen G, Khan A, Rao VT, Shum-Tim D, Prakash S. Genipin-Crosslinked Microencapsulated Human Adipose Stem Cells Augment Transplant Retention Resulting in Attenuation of Chronically Infarcted Rat Heart Fibrosis and Cardiac Dysfunction. Cell Transplant 2012; 21(12): 2735-51.
131. Davis ME, Hsieh PC, Takahashi T, et al. Local myocardial insulinlike growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci USA 2006; 103(21): 8155-60.
132. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007; 116(15): 1683-92.
133. Ye Z, Zhou Y, Cai H, Tan W. Myocardial regeneration: Roles of stem cells and hydrogels. Adv Drug Deliv Rev 2011; 63(8): 688-97.
134. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005; 112(9 Suppl): I173-7.
135. Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng Part B Rev 2008; 14(2): 149-65.
136. Jawad H, Lyon AR, Harding SE, Ali NN, Boccaccini AR. Myocardial tissue engineering. Br Med Bull 2008; 87: 31-47.
137. Leor J, Amsalem Y, Cohen S. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol Ther 2005; 105(2): 151-63.
138. Ryu JH, Kim IK, Cho SW, et al. Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium. Biomaterials 2005; 26(3): 319-26.
139. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 2004; 44(3): 654-60.
140. Martens TP, Godier AF, Parks JJ, et al. Percutaneous cell delivery into the heart using hydrogels polymerizing in situ. Cell Transplant 2009; 18(3): 297-304.
141. Kofidis T, de Bruin JL, Hoyt G, et al. Injectable bioartificial myocardial tissue for large-scale intramural cell transfer and functional recovery of injured heart muscle. J Thorac Cardiovasc Surg 2004; 128(4): 571-8.
142. Zhang P, Zhang H, Wang H, Wei Y, Hu S. Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif Organs 2006; 30(2): 86-93.
143. Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999; 20(1): 45-53.
144. Leor J, Tuvia S, Guetta V, et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol 2009; 54(11): 1014-23.
145. Ruvinov E, Leor J, Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011; 32(2): 565-78.
146. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008; 117(11): 1388-96.
147. Lu WN, Lu SH, Wang HB, et al. Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng Part A 2009; 15(6): 1437-47.
148. Lu S, Wang H, Lu W, et al. Both the transplantation of somatic cell nuclear transfer-and fertilization-derived mouse embryonic stem cells with temperature-responsive chitosan hydrogel improve myocardial performance in infarcted rat hearts. Tissue Eng Part A 2010; 16(4): 1303-15.
149. Liu Z, Wang H, Wang Y, et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials 2012; 33(11): 3093-106.
150. Singelyn JM, Sundaramurthy P, Johnson TD, et al. Catheterdeliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol 2012; 59(8): 751-63.
151. Chang CY, Chan AT, Armstrong PA, et al. Hyaluronic acid-human blood hydrogels for stem cell transplantation. Biomaterials 2012; 33(32): 8026-33.
152. Kraehenbuehl TP, Zammaretti P, Van der Vlies AJ, et al. Threedimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cellresponsive PEG-hydrogel. Biomaterials 2008; 29(18): 2757-66.
153. Wang T, Jiang XJ, Tang QZ, et al. Bone marrow stem cells implantation with alpha-cyclodextrin/MPEG-PCL-MPEG hydrogel improves cardiac function after myocardial infarction. Acta Biomater 2009; 5(8): 2939-44.
154. Zhang S, Holmes TC, DiPersio CM, Hynes RO, Su X, Rich A. Self-complementary oligopeptide matrices support mammalian cell attachment. Biomaterials 1995; 16(18): 1385-93.
155. Davis ME, Motion JP, Narmoneva DA, et al. Injectable selfassembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005; 111(4): 442-50.
156. Wang H, Liu Z, Li D, et al. Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction. J Cell Mol Med 2012; 16(6): 1310-20.
157. Kraehenbuehl TP, Ferreira LS, Hayward AM, et al. Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials 2011; 32(4): 1102-9.
158. Wall ST, Yeh CC, Tu RY, Mann MJ, Healy KE. Biomimetic matrices for myocardial stabilization and stem cell transplantation. J Biomed Mater Res A 2010; 95(4): 1055-66.
159. Yeh YC, Lee WY, Yu CL, et al. Cardiac repair with injectable cell sheet fragments of human amniotic fluid stem cells in an immunesuppressed rat model. Biomaterials 2010; 31(25): 6444-53.
160. Shapira-Schweitzer K, Habib M, Gepstein L, Seliktar D. A photopolymerizable hydrogel for 3-D culture of human embryonic stem cell-derived cardiomyocytes and rat neonatal cardiac cells. J Mol Cell Cardiol 2009; 46(2): 213-24.
161. Habib M, Shapira-Schweitzer K, Caspi O, et al. A combined cell therapy and in-situ tissue-engineering approach for myocardial repair. Biomaterials 2011; 32(30): 7514-23.
162. Duan Y, Liu Z, O'Neill J, Wan LQ, Freytes DO, Vunjak-Novakovic G. Hybrid gel composed of native heart matrix and collagen induces cardiac differentiation of human embryonic stem cells without supplemental growth factors. J Cardiovasc Transl Res 2011; 4(5): 605-15.
163. Wang F, Li Z, Khan M, et al. Injectable, rapid gelling and highly flexible hydrogel composites as growth factor and cell carriers. Acta Biomater 2010; 6(6): 1978-91.